LOS ANGELES, CA / ACCESSWIRE / July 28, 2016 / Lundin Law PC (the "Firm") announces a class action lawsuit has been filed against Lipocine Inc. ("Lipocine" or the "Company") (LPCN) concerning possible violations of federal securities laws between June 30, 2015 and June 28, 2016 (the "Class Period"). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 30, 2016 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
The complaint alleges that during the Class Period, the Company made false and/or misleading statements and/or failed to disclose that: Lipocine's filing of its New Drug Application to the U.S. Food and Drug Administration for LPCN 1021 (the Company's lead product candidate) contained deficiencies; and as a result, Lipocine's statements about its business and operations were false and misleading and/or lacked a reasonable basis. When this information was disclosed, investors suffered losses.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles dedicated to securing shareholders' rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact:
Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/
SOURCE: Lundin Law PC